Idera Pharmaceuticals, Inc.
Extract: Bylaws Amended/Restated (Plain English Desc) from a 8-K on 11/17/2022   Download
SEC Document
SEC Filing

Bylaws Amendment and Restatement

 

On November 17, 2022, the Board of Directors (the “Board”) of Idera Pharmaceuticals, Inc. (the “Company”) approved the adoption of the Second Amended and Restated By-Laws of the Company (the “New Bylaws”), which amend and restate the Amended and Restated Bylaws of the Company, as amended by the First Amendment to the Amended and Restated Bylaws of the Company, dated January 21, 2018 (the “Existing Bylaws”) in their entirety. The New Bylaws amend the Existing Bylaws to, among other things, clarify provisions relating to virtual stockholder meetings and modify the quorum such that presence, in person or by proxy, of the holders of one-third  of the shares of capital stock issued and outstanding and entitled to vote (rather than the majority of the aggregate number of shares of each class of capital stock issued and outstanding and entitled to vote) constitutes a quorum for the transaction of business at stockholder meetings.